Medication info

Losartan I Plus Tablet

Prescription medicationTabletOralExpired
Ingredient · strength
Losartan Potassium›50mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tablet
Manufacturer / importer
Intro Bio Pharma Co., Ltd.
Appearance
Yellow oval film-coated tablet
Packaging
30 tablets/bottle, 300 tablets/bottle
Approval status
Expired

MFDS item code 201908610 · Approved 2019.12.24

This product's status changed to Expired on 2024.12.24. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
○ Adults The usual dose of this medicine is 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg per day are not recommended. The maximum blood pressure-lowering effect generally occurs about 3 weeks after starting treatment. This medicine may be administered with other antihypertensive agents and may be taken without regard to meals. To minimize adverse reactions, start this medicine when the expected effect is not achieved with monotherapy. 1. Substitution therapy: This medicine may replace combination therapy with individually dose-adjusted losartan potassium and hydrochlorothiazide. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Start with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who have hypokalemia despite blood pressure control at this dose: Treatment may be started with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which allows the hydrochlorothiazide dose to be reduced without diminishing the overall blood pressure-lowering effect. Thereafter, monitor the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Use the usual dose if creatinine clearance is 30 mL/min or higher. Use of a loop diuretic rather than a thiazide-type drug is preferable in patients with more severe renal impairment; therefore, use in these patients is not recommended. ○ Patients with hepatic impairment This medicine cannot provide the initial losartan potassium dose of 25 mg required for patients with hepatic impairment who need dose adjustment; therefore, use in these patients is not recommended.
Child dose
○ Children (under 18 years) There is no experience with use in children and adolescents; therefore, the losartan-hydrochlorothiazide combination should not be administered to children or adolescents.

Ingredients

Manufacturer
Intro Bio Pharma Co., Ltd.

Efficacy & effects

Treatment of hypertension not controlled with monotherapy

  • Hypertension
View approved original text

Used for hypertension that is not adequately controlled with monotherapy.

How to take

Adult dose

○ Adults The usual dose of this medicine is 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg per day are not recommended. The maximum blood pressure-lowering effect generally occurs about 3 weeks after starting treatment. This medicine may be administered with other antihypertensive agents and may be taken without regard to meals. To minimize adverse reactions, start this medicine when the expected effect is not achieved with monotherapy. 1. Substitution therapy: This medicine may replace combination therapy with individually dose-adjusted losartan potassium and hydrochlorothiazide. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Start with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who have hypokalemia despite blood pressure control at this dose: Treatment may be started with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which allows the hydrochlorothiazide dose to be reduced without diminishing the overall blood pressure-lowering effect. Thereafter, monitor the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Use the usual dose if creatinine clearance is 30 mL/min or higher. Use of a loop diuretic rather than a thiazide-type drug is preferable in patients with more severe renal impairment; therefore, use in these patients is not recommended. ○ Patients with hepatic impairment This medicine cannot provide the initial losartan potassium dose of 25 mg required for patients with hepatic impairment who need dose adjustment; therefore, use in these patients is not recommended.

Child dose

○ Children (under 18 years) There is no experience with use in children and adolescents; therefore, the losartan-hydrochlorothiazide combination should not be administered to children or adolescents.

Precautions

This medication can cause serious harm to the fetus if taken during pregnancy, especially during the second and third trimesters. Therefore, it should be discontinued immediately upon confirmation of pregnancy. This medication should not be used in patients with certain medical conditions, such as those with anuria or hypersensitivity to certain drugs, severe liver impairment, kidney impairment, or pregnant women. Patients with very low blood pressure, poor kidney function, a history of liver disease, and those with electrolyte imbalance should use this medication cautiously, and may require regular monitoring. Since this medication acts to lower blood pressure, dizziness or drowsiness may occur, and caution is advised when driving or operating machinery. During treatment, regular monitoring of blood electrolyte levels, liver function, and kidney function should be conducted to ensure no abnormalities occur, with particular attention paid to potassium levels. This medication can interact with other drugs, so if you are taking any other medications, be sure to consult with your doctor or pharmacist. Additionally, it is advisable to avoid potassium supplements or potassium-containing salt substitutes during treatment and to refrain from consuming grapefruit juice concurrently. The Hydrochlorothiazide component may increase sensitivity to sunlight, raising the risk of skin cancer, so it is important to limit sun exposure and regularly check the condition of the skin. The safety and efficacy of this medication have not been established in children and adolescents, so it is not used in these populations. If any unusual symptoms or side effects occur during treatment, consult healthcare professionals immediately to receive appropriate care.

Side effects

  • Craniosynostosis
  • anuria
  • hypotension
  • renal failure
  • death
  • abdominal pain
  • edema
  • palpitations
  • lumbago
  • dizziness
Show 130 more
  • cough
  • sinusitis
  • upper respiratory tract infection
  • rash
  • angioedema
  • skin desquamation
  • hemolysis
  • chest pain
  • facial edema
  • fever
  • orthostatic hypotension
  • syncope
  • angina
  • arrhythmia
  • cerebrovascular accident
  • hypotension
  • myocardial infarction
  • secondary atrioventricular block
  • anorexia
  • constipation
  • toothache
  • dry mouth
  • dyspepsia
  • flatulence
  • gastritis
  • vomiting
  • malaise
  • anemia
  • gout
  • arm pain
  • arthralgia
  • arthritis
  • fibromyalgia
  • hip pain
  • joint swelling
  • knee pain
  • leg pain
  • muscle cramps
  • muscle weakness
  • musculoskeletal pain
  • myalgia
  • shoulder pain
  • muscle rigidity
  • anxiety
  • anxiety disorder
  • ataxia
  • confusion
  • depression
  • nightmares
  • sensory impairment
  • insomnia
  • decreased libido
  • memory impairment
  • migraine
  • hypersensitivity
  • panic disorder
  • sensory abnormalities
  • peripheral neuropathy
  • sleep disorders
  • drowsiness
  • tremors
  • dizziness
  • dyspnea
  • epistaxis
  • nasal congestion
  • pharyngeal discomfort
  • respiratory congestion
  • rhinitis
  • venous sinus disorder
  • chest discomfort
  • alopecia
  • dermatitis
  • dry skin
  • purpura
  • erythema
  • flushing
  • phototoxic reaction
  • pruritus
  • sweating
  • urticaria
  • blurred vision
  • ocular pain
  • burning sensation
  • conjunctivitis
  • visual impairment
  • taste disturbance
  • tinnitus
  • erectile dysfunction
  • nocturia
  • pollakiuria
  • urinary tract infection
  • weakness
  • pancreatitis
  • jaundice
  • sialadenitis
  • convulsions
  • gastrointestinal irritation
  • aplastic anemia
  • agranulocytosis
  • leukopenia
  • thrombocytopenia
  • purpura
  • necrotizing vasculitis
  • fever
  • pneumonia
  • pulmonary edema
  • acute respiratory distress syndrome
  • hyperglycemia
  • diabetes
  • hyperuricemia
  • muscle spasm
  • restlessness
  • renal failure
  • renal impairment
  • interstitial nephritis
  • skin and mucous membrane syndrome
  • erythema multiforme
  • toxic epidermal necrolysis
  • transient blurred vision
  • xanthopsia
  • acute myopia
  • acute closed-angle glaucoma
  • dry cough
  • vasculitis
  • anaphylactic reaction
  • hepatitis
  • erythroderma
  • hyperkalemia
  • hyponatremia
  • rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light and should be stored in a container that does not allow light exposure. Furthermore, it is important to store the medication safely at room temperature between 1 degree and 30 degrees.

Appearance and packaging

Appearance

Yellow oval film-coated tablet

Package unit

30 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.